Lab
L. Medicine Labs, LLC
L. Medicine Labs, LLC was paid $2.85M by Medicaid between Mar 2018 and Dec 2024, across 117 billing codes. Its largest line is 87389, Infectious agent antigen detection by immunoassay technique, HIV-1 antigen with HIV-1 and HIV-2 antibodies — 14% of everything it billed.
33Billing provider infoL. MEDICINE LABS, LLC
BERWYN, IL 60402
BERWYN, IL 60402
33aNPI1053819722assigned 01/29/2018
33bProvider typeClinical Medical Laboratory
28Total paid$2.85M
24GClaims312,728
24DCodes billed117
24AFirst – last monthMar 2018 – Dec 2024
Compared with peers
Next to other Clinical Medical Laboratory providers in Illinois
Rank by total paid#54 of 235
Median peer was paid$123K
This provider vs. median23×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 27,276 | $331K | |
| 2019 | 39,883 | $500K | |
| 2020 | 44,307 | $362K | |
| 2021 | 49,401 | $435K | |
| 2022 | 46,672 | $404K | |
| 2023 | 53,035 | $432K | |
| 2024incomplete | 52,154 | $384K |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 87389 | Infectious agent antigen detection by immunoassay technique, HIV-1 antigen with HIV-1 and HIV-2 antibodies | 14% | 10,674 | 9,110 | $392K |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | 8.8% | 9,401 | 7,737 | $251K |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | 8.7% | 9,353 | 7,751 | $247K |
| 84443 | Thyroid stimulating hormone (TSH) | 6.4% | 19,209 | 17,053 | $183K |
| 80053 | Comprehensive metabolic panel | 5.1% | 25,549 | 22,708 | $146K |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | 4.0% | 1,424 | 1,254 | $115K |
| 87624 | Infectious agent detection by nucleic acid; human papillomavirus (HPV), high-risk types | 3.3% | 3,452 | 3,133 | $94K |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | 3.3% | 1,892 | 1,716 | $93K |
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | 3.2% | 13,927 | 12,568 | $92K |
| 88175 | Cytopathology, cervical or vaginal, any reporting system; collected in preservative fluid, automated thin layer | 2.9% | 4,685 | 4,300 | $83K |
| 83036 | Hemoglobin; glycosylated (A1C) | 2.6% | 19,308 | 17,368 | $73K |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | 2.2% | 18,809 | 16,676 | $61K |
105 more codes
| 80061 | Lipid panel | 2.1% | 21,911 | $61K |
| 86480 | 2.1% | 2,113 | $61K | |
| 85027 | 1.9% | 15,267 | $55K | |
| 86803 | 1.7% | 5,022 | $48K | |
| 87086 | Culture, bacterial; quantitative colony count, urine | 1.4% | 6,061 | $39K |
| 87340 | 1.3% | 4,755 | $37K | |
| 87480 | 1.2% | 2,063 | $35K | |
| 87510 | 1.2% | 2,052 | $35K | |
| 82607 | 1.1% | 4,638 | $33K | |
| 83655 | 1.1% | 4,364 | $30K | |
| 86787 | <1% | 2,906 | $26K | |
| 87660 | <1% | 2,090 | $24K | |
| 84403 | <1% | 1,604 | $23K | |
| 87631 | <1% | 416 | $22K | |
| 86780 | <1% | 2,381 | $20K | |
| U0005 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 | <1% | 825 | $20K |
| 88305 | Level IV - Surgical pathology, gross and microscopic examination | <1% | 740 | $19K |
| 87653 | <1% | 621 | $18K | |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 3,881 | $18K |
| 84439 | <1% | 3,186 | $17K | |
| 83001 | <1% | 1,669 | $17K | |
| 86038 | <1% | 1,350 | $16K | |
| 82746 | <1% | 2,298 | $16K | |
| 84702 | <1% | 2,956 | $16K | |
| 86762 | <1% | 3,082 | $15K | |
| 86592 | <1% | 5,454 | $14K | |
| 86003 | <1% | 461 | $14K | |
| 82570 | <1% | 4,543 | $13K | |
| 87661 | Infectious agent detection by nucleic acid; Trichomonas vaginalis, amplified probe | <1% | 798 | $12K |
| 82043 | <1% | 4,762 | $12K | |
| 86850 | <1% | 3,370 | $11K | |
| 87507 | <1% | 65 | $11K | |
| 81001 | <1% | 6,812 | $11K | |
| 87186 | <1% | 1,450 | $10K | |
| 84146 | <1% | 1,228 | $9K | |
| 86901 | <1% | 3,409 | $9K | |
| 87801 | Infectious agent detection by nucleic acid; amplified probe, multiple organisms | <1% | 234 | $9K |
| 82728 | <1% | 1,839 | $8K | |
| 84466 | <1% | 1,742 | $8K | |
| 87651 | Infectious agent detection by nucleic acid; Streptococcus, group A, amplified probe | <1% | 195 | $8K |
| 83540 | <1% | 2,188 | $8K | |
| 82105 | <1% | 887 | $8K | |
| 82950 | <1% | 2,703 | $7K | |
| 83020 | <1% | 1,223 | $7K | |
| 86900 | <1% | 3,404 | $7K | |
| 83013 | <1% | 608 | $6K | |
| 86140 | <1% | 2,335 | $6K | |
| 82670 | <1% | 809 | $5K | |
| G0103 | Prostate cancer screening; prostate specific antigen test (psa) | <1% | 612 | $5K |
| 84153 | <1% | 504 | $5K | |
| 81003 | <1% | 3,904 | $5K | |
| 88142 | <1% | 1,263 | $4K | |
| 85610 | <1% | 1,687 | $4K | |
| 87081 | <1% | 978 | $4K | |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | <1% | 131 | $3K |
| 85652 | <1% | 2,068 | $3K | |
| 86593 | <1% | 1,016 | $3K | |
| 86431 | <1% | 552 | $3K | |
| 82247 | <1% | 594 | $3K | |
| 86769 | <1% | 54 | $2K | |
| 87070 | <1% | 370 | $2K | |
| 85018 | <1% | 1,473 | $2K | |
| 83735 | <1% | 563 | $2K | |
| 84402 | <1% | 130 | $2K | |
| 85014 | <1% | 1,433 | $2K | |
| 83550 | <1% | 262 | $2K | |
| 85651 | <1% | 423 | $2K | |
| 82785 | <1% | 394 | $2K | |
| 86376 | <1% | 346 | $2K | |
| 82248 | <1% | 670 | $2K | |
| 85730 | <1% | 474 | $1K | |
| 83002 | <1% | 251 | $1K | |
| 82550 | <1% | 408 | $1K | |
| 84436 | <1% | 360 | $1K | |
| 80050 | General health panel | <1% | 31 | $1K |
| 82951 | <1% | 141 | $1K | |
| 87077 | <1% | 604 | $999.99 | |
| 86200 | <1% | 162 | $977.10 | |
| 83021 | <1% | 83 | $951.39 | |
| 87205 | <1% | 517 | $922.30 | |
| 36415 | Collection of venous blood by venipuncture | <1% | 1,982 | $857.41 |
| 86235 | <1% | 24 | $823.80 | |
| 0352U | <1% | 278 | $725.76 | |
| 84481 | <1% | 87 | $697.02 | |
| 80076 | <1% | 167 | $621.33 | |
| 84550 | <1% | 284 | $602.60 | |
| 84480 | <1% | 122 | $568.53 | |
| 83970 | <1% | 30 | $548.49 | |
| 86706 | <1% | 76 | $531.35 | |
| 85007 | <1% | 134 | $441.00 | |
| 82627 | <1% | 94 | $395.39 | |
| 85660 | <1% | 89 | $391.58 | |
| 81220 | CFTR (cystic fibrosis transmembrane conductance regulator) gene analysis; common variants | <1% | 52 | $334.64 |
| 80074 | <1% | 15 | $299.53 | |
| 86039 | <1% | 47 | $252.84 | |
| 82952 | <1% | 123 | $249.79 | |
| 82784 | <1% | 30 | $216.54 | |
| 81015 | <1% | 59 | $143.52 | |
| 82565 | <1% | 44 | $83.25 | |
| 83690 | <1% | 12 | $78.48 | |
| 86765 | <1% | 12 | $63.24 | |
| 86735 | <1% | 12 | $59.94 | |
| 87102 | <1% | 15 | $51.90 | |
| G0123 | Screening cytopathology, cervical or vaginal (any reporting system), collected in preservative fluid, automated thin layer preparation, screening by cytotechnologist under physician supervision | <1% | 15 | $51.51 |
| 84156 | <1% | 14 | $19.04 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialLUKASICK, MELISSA (REGIONAL CHIEF FINANCIAL OFFICER)
| Provider | Location | Paid |
|---|---|---|
| Loyola Medicine Transport LLC | Melrose Park, IL | $2.66M |
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.